Relationship between depth of response and outcome in multiple myeloma

Journal of Clinical Oncology

Volumn 25, Issue 31, 2007, Pages 4933-4937

  Dingli, David ^a   Pacheco, Jorge M ^a   Nowakowski, Grzegorz S ^a   Kumar, Shaji K ^a   Dispenzieri, Angela ^a   Hayman, Suzanne R ^a   Lacy, Martha Q ^a   Gastineau, Dennis A ^a   Gertz, Morie A ^a  

^a UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TUMOR BURDEN;

EID: 36849031848     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.7879     Document Type: Article

References (37)

1. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 351:1860-1873, 2004
2. Barlogie B, Shaughnessy J, Tricot G, et al: Treatment of multiple myeloma. Blood 103:20-32, 2004
3. Richardson P, Hideshima T, Anderson KC: An update of novel therapeutic approaches for multiple myeloma. Curr Treat Options Oncol 5:227-238, 2004
4. Rajkumar SV, Blood E, Vesole D, et al: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431-436, 2006
5. Richardson PG, Blood E, Mitsiades CS, et al: A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458-3464, 2006
6. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
7. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med 335:91-97, 1996
8. Fermand JP, Ravaud P, Chevret S, et al: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92:3131-3136, 1998
9. Barlogie B, Jagannath S, Desikan KR, et al: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55-65, 1999
10. Attal M, Harousseau JL, Facon T, et al: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502, 2003
11. Child JA, Morgan GJ, Davies FE, et al: Highdose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883, 2003
12. Alexanian R, Weber D, Giralt S, et al: Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 27:1037-1043, 2001
13. Nadal E, Gine E, Blade J, et al: High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: Predictors of complete remission. Bone Marrow Transplant 33:61-64, 2004
14. Bladé J, Rosinol L, Sureda A, et al: High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Longterm results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106:3755-3759, 2005
15. Fermand JP, Katsahian S, Divine M, et al: High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23:9227-9233, 2005
16. Barlogie B, Kyle RA, Anderson KC, et al: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 24:929-936, 2006
17. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
18. Gianni AM, Bregni M, Siena S, et al: Highdose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997
19. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med 331:896-903, 1994
20. Sullivan PW, Salmon SE: Kinetics of tumor growth and regression in IgG multiple myeloma. J Clin Invest 51:1697-1708, 1972
21. Barlogie B, Jagannath S, Vesole DH, et al: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789-793, 1997
22. Bergsagel PL, Kuehl WM: Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23:6333-6338, 2005
23. Bladé J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT - European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
24. Durie BG, Jacobson J, Barlogie B, et al: Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol 22:1857-1863, 2004
25. Rajkumar SV, Fonseca R, Lacy MQ, et al: Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant 23:1261-1266, 1999
26. Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin Oncol 23:3412-3420, 2005
27. Porrata LF, Adjei AA: The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours. Br J Cancer 85:484-489, 2001
28. Dingli D, Pacheco JM, Dispenzieri A, et al: The serum M-spike and transplant outcome in patients with multiple myeloma. Cancer Sci 98:1035-1040, 2007
29. Dingli D, Pacheco JM, Dispenzieri A, et al: In vivo and in silico studies on single versus multiple transplants for multiple myeloma. Cancer Sci 98:734-739, 2007
30. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163-169, 1986
31. Norton L: Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 24:S10-3-S10-10, 1997
32. Norton L: Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 6:30-35, 2001 (suppl)
33. Cavo M, Tosi P, Zamagni E, et al: Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 Clinical Study. J Clin Oncol 25:2434-2441, 2007
34. Kyle RA: Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am 6:347-358, 1992
35. Barlogie B Jr, Shaughnessy JD: Early results of total therapy II in multiple myeloma: Implications of cytogenetics and FISH. Int J Hematol 76:337-339, 2002 (suppl)
36. Qazilbash MH, Saliba RM, Aleman A, et al: Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma 47:1360-1364, 2006
37. Dingli D, Nowakowski GS, Dispenzieri A, et al: Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 6:384-388, 2006